The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Eli Lilly and Company (LLY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$903.02. During the previous open market day, the price has varied from a low of USD895.61 to a high of USD908.6699. Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Eli Lilly and Company
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Eli Lilly and Company. Find the share by name or ticker symbol: LLY. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eli Lilly and Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$903.02, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Eli Lilly and Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Eli Lilly and Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Eli Lilly and Company shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Eli Lilly and Company's shares ever split?
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Eli Lilly and Company shares at a glance
Information last updated 2026-03-18.
| 52-week range | US$620.4646 - US$1132.0606 |
|---|---|
| 50-day moving average | US$1031.6926 |
| 200-day moving average | US$890.9305 |
| Target price | US$1209.3448 |
| PE ratio | 40.0022 |
| Dividend yield | US$6 (0.64%) |
| Earnings per share (TTM) | US$22.95 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Eli Lilly and Company price performance over time
Historical closes compared with the last close of $903.02
| 1 week (2026-03-18) | -1.64% |
|---|---|
| 1 month (2026-02-25) | -12.23% |
| 3 months (2025-12-26) | -16.21% |
| 6 months (2025-09-26) | 24.63% |
| 1 year (2025-03-26) | 9.22% |
|---|---|
| 2 years (2024-03-26) | 16.53% |
| 3 years (2023-03-24) | 168.65% |
| 5 years (2021-03-25) | 393.21% |
Is it a good time to buy Eli Lilly and Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Eli Lilly and Company stock?
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's P/E ratio
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Eli Lilly and Company shares trade at around 40x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's PEG ratio
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9977. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$31.7 billion (£23.9 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure stock profitability.
Eli Lilly and Company share price volatility
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$620.4646 up to US$1132.0606. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.434. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company financials
| Revenue TTM | US$65.2 billion |
|---|---|
| Operating margin TTM | 44.9% |
| Gross profit TTM | US$54.1 billion |
| Return on assets TTM | 19.42% |
| Return on equity TTM | 101.16% |
| Profit margin | 31.67% |
| Book value | 29.655 |
| Market capitalisation | US$821.7 billion |
| EBITDA | US$31.7 billion |
TTM: trailing 12 months
Eli Lilly and Company share dividends
Dividend payout ratio: 25.73% of net profits
Recently Eli Lilly and Company has paid out, on average, around 25.73% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.68% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.68% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $6 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 March 2026. The latest dividend was paid out to all shareholders who bought their shares by 12 February 2026 (the "ex-dividend date").
Eli Lilly and Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Eli Lilly and Company's total ESG risk score
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Eli Lilly and Company overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Betashares Direct review
Pay zero brokerage when you invest in ASX ETFs using Betashares Direct.
-
Best performing stocks on the ASX
Top gainers included EQ Resources, Viva Energy Group and Elsight.
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
ASX lithium stocks
Lithium is a precious metal with increasing demand. Here’s what you should know before you invest.
-
What are the best AI stocks on the ASX in 2026? Stocks and ETFs to watch
Here's what investors should know before adding AI stocks to their portfolios.
-
Vanguard Personal Investor review
We took a look at the features and fees of the latest share trading platform.
-
How to invest in Nasdaq from Australia
Find out how you can invest in Nasdaq and compare a range of leading brokers that let you invest in US stocks cheaply and quickly.
-
How to invest in index funds in Australia
Index funds are a hot topic right now, but how do you actually invest in them?
-
Stake review: A trading platform for AU and US stocks
Stake is a trading platform for Australians who want value for money when trading. Gain access to one of the cheapest CHESS-sponsored and US trading platforms in Australia, and $3 brokerage in the US.
-
Totality (formerly Saxo) Australia review: Share trading platform
Totality allows you to trade over 60,000 instruments on 50 global stock exchanges and provides lower commissions for active traders.